Popular Articles
Today Week Month Year


Guinea pigs: Pfizer gets FDA approval to experiment on pregnant women with new RSV vaccine linked to premature birth
By Lance D Johnson // Dec 06, 2023

After profiting from one of the most dangerous and ineffective vaccines in world history, Pfizer is ready to advance a new RSV vaccine that is linked to premature birth and neonatal death risk. Pfizer just received approval from the Food and Drug Administration (FDA) to experiment on pregnant women with their new RSV vaccine, which goes by the brand name Abrysvo. The new jab was fast tracked through phase three clinical trials and will be recommended to pregnant women 32-36 weeks of gestational age. The new jab will be promoted as a preventative for respiratory syncytial virus (RSV). It was also approved by the European Commission in August 2023, and is awaiting approval in the United Kingdom.

First clinical trials find increase in premature birth and neonatal death after RSV vaccination

The first clinical trials for RSV vaccines found an increase in premature birth and neonatal death after pregnant women were vaccinated. The majority of the commissioners at the FDA are ignoring these safety signals because they believe the benefits of vaccination outweigh the risk of severe RSV in infants. While Pfizer admits to studying preterm birth as an “adverse event of special interest,” the company did not inform pregnant women of this risk when women were lined up to participate in the phase three clinical trials.

This safety signal was first detected during clinical trials for a similar vaccine developed by GlaxoSmithKline (GSK). Both Pfizer and GSK's RSV vaccines are similar because they use recombinant RSV F protein as an antigen.

We are building the infrastructure of human freedom and empowering people to be informed, healthy and aware. Explore our decentralized, peer-to-peer, uncensorable Brighteon.io free speech platform here. Learn about our free, downloadable generative AI tools at Brighteon.AI. Every purchase at HealthRangerStore.com helps fund our efforts to build and share more tools for empowering humanity with knowledge and abundance.

When the issue of preterm birth and neonatal death was first raised, GlaxoSmithKline halted their Phase 3 vaccine study on February 28, 2022. Pfizer, on the other hand, carelessly plunged forward with their experiment on pregnant women and unborn babies.

GSK had to halt their trials because there was a marked increase in preterm birth in pregnant women living in low and middle-income countries, especially in South Africa. Pfizer also documented a numerical increase in preterm birth in the phase 2 and 3 clinical studies, but the risk was later considered "not statistically significant."

Of the 14 members on the FDA’s vaccines and related biological products advisory committee, four of the members voted against the Pfizer RSV vaccine. The other ten members supported the vaccine as safe and gave it FDA approval for pregnant women. The FDA is requiring Pfizer to conduct post-marketing studies to “assess the signal of serious risk of pre-term birth.” This means another risky vaccine experiment will be carried out on pregnant women who are told to just "trust the science."

Pfizer refuses to provide adequate informed consent to pregnant women

An article published in the British Medical Journal discusses the ethical concerns over informed consent for pregnant women in Pfizer’s RSV vaccine trial. Charles Weijer, a bioethics professor at Western University in London, Canada spoke with the BMJ about the importance of informing pregnant women about the preterm labor risks in Pfizer’s clinical trial.

Because life-threatening risks were observed in GSK's RSV vaccine trial, Pfizer had an ethical duty to inform participants of this risk beforehand. If Pfizer would have provided adequate informed consent, then women considering the injection would be able to reconsider the serious risks, and women who already got the vaccine would be able to seek additional medical advice and follow-up.

"Any failure to provide new and potentially important safety information data to trial participants is ethically problematic," Weijer said.

To make matters worse, Pfizer’s trial consent forms claimed that the RSV vaccine candidate was “risk free for the baby.” However, when ethics experts reviewed the claim, they called it “misleading” and “irresponsible.”

Moreover, when BMJ researchers contacted government health authorities in 18 countries where Pfizer had setup trial sites, they were told by more than 80 trial investigators that none of the pregnant women received informed consent on this life-or-death issue! This is a serious breach of medical ethics and scientific integrity. Babies are being sacrificed to boost Pfizer’s profits, and pregnant women are being exploited. More researchers and regulators must relinquish their blind trust in vaccination and take a principled stand against medical fraud and malfeasance that is taking place behind the scenes.

Sources include:

Expose-News.com

ClinicalTrialsArena.com

BMJ.com



Take Action:
Support NewsTarget by linking to this article from your website.
Permalink to this article:
Copy
Embed article link:
Copy
Reprinting this article:
Non-commercial use is permitted with credit to NewsTarget.com (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.

NewsTarget.com © 2022 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. NewsTarget.com is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. NewsTarget.com assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published on this site. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
News Target uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Close
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.